In breast cancer, short hairpin RNA screening and sequencing for tamoxifen resistance or sensitivity in patients with ER+ breast cancer patients revealed that the downregulation of VSTM4 can augment the sensitivity to tamoxifen treatment [48]. Here, VSTM4 is linked to breast carcinoma.